Physician profile
Pouya Mafi
NPI 1790212256
$2,739.25
in general payments reported to CMS, 2019-2025
14 companies · $264 in 2025
The $264 reported for 2025 was more than what 81% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.53 · 2021: $986 · 2022: $567 · 2023: $391 · 2024: $506 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.29 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $527.94 | 2021-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $468.27 | 2021-2025 | Kimyrsa, Rezzayo |
| Alexion Pharmaceuticals, INC. | $248.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $238.62 | 2021-2024 | Xarelto |
| Ferring Pharmaceuticals INC. | $129.05 | 2023 | Rebyota |
| La Jolla Pharmaceutical Company | $124.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $123.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $121.06 | 2025 | Zerbaxa |
| Astrazeneca Pharmaceuticals Lp | $97.48 | 2020-2023 | Lokelma |
| Vifor Pharma, INC. | $45.67 | 2021-2022 | |
| Shionogi INC | $41.89 | 2024 | Fetroja |
| Mallinckrodt Hospital Products INC. | $18.33 | 2023 | Terlivaz |
| Pfizer INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pouya Mafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.